All subjects completed the 5d metabolic rate assessment. No significant changes in body weight were detected during this period (0•15 (SE 0•18) kg; range: 2 1•1 to 1•3; P¼ 0•41). Capsinoids’ capsules were well tolerated and adverse events were similar across treatments (P¼ 0•09). Likewise, systolic and diastolic blood pressures were unchanged over time and unaffected by capsinoids. A small but statistically significant increase in body temperature was observed when body temperature was compared at 2 50 and 120 min after ingestion of the capsules (35•9 (SE 0•1) to 36•0 (SE 0•0)8C; P¼ 0•02), but was not affected by treatment (P¼ 0•16).